“…Between 0.1% and 2.0% of patients treated with tirofiban, eptifibatide, and other drugs of this class evaluated in clinical trials experienced acute thrombocytopenia, often severe, within a few hours of starting treatment, 5 a complication now known to be caused by Abs that recognize ␣ IIb / 3 in a complex with the ligand mimetic drug being administered. [6][7][8][9][10] A unique feature of such Abs is that they can occur naturally in persons never previously exposed to one of these drugs, enabling thrombocytopenia to develop within a few hours of starting treatment. 7,11 Various mechanisms have been identified by which druginduced Abs cause thrombocytopenia.…”